ClinicalTrials.gg
Status unknownNCT04853069Updated Apr 21, 2021

Oestrogen Treatment for COVID-19 Symptoms

A Phase 2 interventional study of Transdermal estradiol gel in COVID-19, sponsored by Hamad Medical Corporation. Status unknown at 1 site in Qatar. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-21.

Sponsored by Hamad Medical Corporation · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in COVID-19 by Hamad Medical Corporation — none open to participants now, none under way, none of them phase 3. COVID-19 · Hamad Medical Corporation.

Planned enrollment
Largest of 11
2,000 · median 200
Started
2021
with 4 others
Phase 2
2 of 17
none open now
Registered
11th of 17
by date

Among the 17 studies in COVID-19 by Hamad Medical Corporation, this one has the largest planned enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2021, is one of 2 in phase 2, and was the 11th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 17 studies in COVID-19 by Hamad Medical Corporation is open now. The open studies under COVID-19, anywhere →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in COVID-19 by Hamad Medical Corporation as a file.
02

Study summary

The aim of this trial is to determine whether oestrogen treatment mitigates disease progression and severity in confirmed COVID19.

Read the detailed description

It is known that (i) women are relatively protected from the impacts of other respiratory viruses, and that oestrogen may partly mediate this effect (ii) Oestrogen protects rodents from SARS-CoV-1 related mortality (iii) Women are relatively protected from developing or dying from severe COVID-19 and (iv) Postmenopausal women taking oestrogen replacement appear less likely to suffer Covid19-related critical illness. These effects may be mediated through oestrogen-related immunomodulation. In addition, however, 17β estradiol reduces expression of ACE2 (the receptor protein through which SARS-CoV-2 gains cellular entry) in tissues such as the kidney. As such, supplemental oestrogen may represent an effective therapy for Covid19.

We will randomise adult men and postmenopausal women with confirmed Covid19 disease to receive 10 days of transdermal oestrogen (3mg/day). The primary endpoint will be evidence of disease progression, indicated by hospitalisation (mild cases) or need for mechanical ventilation or death within 28 days of randomisation for those hospiatlsied. Secondary outcomes will include hospital mortality, duration of hospital admission, admission to ICU/ HDU facility, ICU/ HDU length of stay, need for renal replacement therapy, receipt and duration of invasive mechanical ventilation, cause-specific mortality and time to being fit for hospital discharge

.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • COVID-19
  • Oestrogen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute Covid-19 disease (PCR-confirmed or clinically diagnosed with high certainty)
  • Adult males > 18 years of age OR
  • women (spontaneous amenorrhoea for >12 months in the absence of any other cause)

Exclusion criteria

Exclusion Criteria:

Women:

  • taking oestrogen supplements or oestrogen receptor antagonists
  • with abnormal genital bleeding
  • with a history of breast cancer
  • with a history of endometrial or ovarian cancer
  • with untreated endometrial hyperplasia

Men:

  • taking hormone therapies (e.g. for prostate cancer)

Any subject:

  • failure to obtain consent
  • taking lamotrigine
  • with a thromboembolic disorder (e.g. Protein C or Protein S deficiency, antithrombin III deficiency)
  • with pre-existing liver or renal disease
  • with known allergy to exogenous oestrogens
  • with a history of porphyria
  • with a history of thromboembolic event including deep vein thrombosis, thromboembolic stroke or pulmonary emboli
  • taking part in another interventional clinical trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Active comparator
    Oestrogen Therapy

    Patients will receive standard care + transdermal 17ß-estradiol gel (3 mg) for ten days.

    Drug: Transdermal estradiol gel

  • No intervention
    Control Group

    Patients will receive only standard care.

Interventions

  • Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.

    Also known as: oestrogel, estrogel

06

What researchers measure

Primary outcomes

  1. Evidence of disease progression for mild cases

    Proportion hospitalised within 28 days

    Time frame: 28 days

  2. Evidence of disease progression in hospitalised patients (moderate and severe cases)

    Proportion requiring mechanical ventilation or dying within 28 days

    Time frame: 28 days

Secondary outcomes

  1. Hospital mortality

    Rate of mortality

    Time frame: 28 days

  2. Duration of hospital admission

    Length of stay at hospital

    Time frame: 28 days

  3. Admission to ICU/ HDU facility

    Length of stay at ICU/HDU facility

    Time frame: 28 days

  4. Need for renal replacement therapy

    Proportion requiring renal replacement therapy

    Time frame: 28 days

  5. Ventilation

    Proportion requiring mechanical ventilation within 28 days

    Time frame: 28 days

  6. Time to being fit for hospital discharge

    Time of discharge

    Time frame: 28 days

07

Study locations

1 site
  • Hamad Medical Corporation
    Doha, PO Box 3050, Qatar
    • Adel Ganaw, MD · Principal investigator
    • Michael P Frenneaux, MD · Principal investigator
    • Melanie Madhani, PhD · Sub investigator
    • Hugh Montgomery, MD · Sub investigator
    • Moad Ehfeda, MD · Sub investigator
    • Ali Omrani, MD · Sub investigator
    • Muna Almaslamani, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2021; primary completion for Feb 2022, 9 months later.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's planned 9 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2021
First posted
Apr 21, 2021
StartEst.
May 17, 2021
Primary completionEst.
Feb 28, 2022
CompletionEst.
Mar 31, 2022
Last update
Apr 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04853069
Collaborators
Laboratoires Besins International
Responsible party
Sponsor
First posted
Apr 21, 2021
Start date
May 17, 2021 (estimated)
Primary completion
Feb 28, 2022 (estimated)
Completion
Mar 31, 2022 (estimated)
Last update
Apr 21, 2021

Study contacts

Michael P Frenneaux
Contact
MFrenneaux@hamad.qa
0097455425733
Adel Ganaw
Contact
aganaw@hamad.qa
0097433606110

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion